GNLX

#3235
Genelux Corporation Common Stock
2.98
+4.56%
セクター:
ベース:
利益通貨:
日中レンジ
2.98
2.98
1年のレンジ
1.99
8.54
1日の変化
+4.56%
月次変化
+2.05%
6か月変化
-19.46%
1年の変化
-31.18%
以前の終値
2.85
Open
2.98
Bid
Ask
Low
2.98
High
2.98
ボリューム
7
Open full chart

Financials

Overview 明細書 Statistics Dividends
Quarterly Annual
  • Market Capitalization 109.87 M
  • Employee 24
  • Founded 2001
  • CEO N/A
  • Website www.genelux.com
  • Headquarter Delaware, United States
  • FIGI BBG0044BNBX6
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-4.83
Price to sales ratio
—
Dividends per share
—
Dividend yield %
—

Genelux Corporation

Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity. The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME.

ニュース